The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.50 (2.86%)
Spread: 1.00 (5.714%)
Open: 17.50
High: 18.00
Low: 17.50
Prev. Close: 17.50
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Jan 2023 16:28

RNS Number : 3057O
SkinBioTherapeutics PLC
30 January 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights areattachedii:

 

SKINBIOTHERAPEUTICS PLC

1b. Please indicate if the issuer is a non-UK issuer(please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification(please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

x

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Optibiotix Health Plc

City and country of registered office (if applicable)

UK

4. Full name of shareholder(s)(if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

05/01/2023

6. Date on which issuer notified (DD/MM/YYYY):

30/01/2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights at- tached to shares (to- tal of 8. A)

% of voting rights through financial instru- ments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights of is- suervii

Resulting situation on the date on which

threshold was crossed or reached

 

18.71%

 

173,138,854

Position of previous notification (if applicable)

 

20.67%

 

1

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

32,402,206

18.71%

SUBTOTAL 8. A

32,402,206

18.71%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

 

Type of financial in- strument

 

Expiration datex

 

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

 

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration datex

Exercise/ Conversion Pe-

riod xi

Physical or cash

settlementxii

Number of voting rights

 

% of voting rights

SUBTOTAL

8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv

(please add additional rows as necessary)

 

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial in- struments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

30/01/2023

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBMMFTMTTJBAJ
Date   Source Headline
19th Mar 20204:42 pmRNSSecond Price Monitoring Extn
19th Mar 20204:38 pmRNSPrice Monitoring Extension
19th Mar 20202:06 pmRNSSecond Price Monitoring Extn
19th Mar 20202:01 pmRNSPrice Monitoring Extension
19th Mar 202011:05 amRNSSecond Price Monitoring Extn
19th Mar 202011:00 amRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSDistribution Agreement for SlimBiome® Medical
16th Mar 202011:56 amRNSDirector’s Dealing
12th Mar 20204:44 pmRNSSecond Price Monitoring Extn
12th Mar 20204:39 pmRNSPrice Monitoring Extension
12th Mar 20202:05 pmRNSSecond Price Monitoring Extn
12th Mar 20202:00 pmRNSPrice Monitoring Extension
12th Mar 20207:00 amRNSNew partner for LPLDL® in Bulgaria
11th Mar 20207:00 amRNSExtension of LPLDL® supply agreement with SACCO
25th Feb 20207:00 amRNSMarketing update
17th Feb 20207:06 amRNSDistributor agreement for LPLDL®
12th Feb 20207:00 amRNSExtension of LPLDL® into Dairy Products
31st Jan 20207:00 amRNSLaunch of SlimBiome® in North America
28th Jan 20207:00 amRNSExtension of term and territories for products
27th Jan 20207:00 amRNSLaunch of LPLDL® product with AlfaSigma
17th Jan 20207:00 amRNSTrading Update
8th Jan 20207:00 amRNSLPLDL® reduces high blood pressure
7th Jan 20207:00 amRNSLaunch of SlimBiome® range in Holland & Barrett
19th Dec 20197:00 amRNSSlimBiome® distribution agreement for Germany
17th Dec 20197:00 amRNSAnthem BioPharma launches two products in India
9th Dec 20197:00 amRNSDistribution agreement for CholBiome®x3
6th Dec 20197:00 amRNSGoFigure® and SlimBiome® commercial updates
5th Dec 20197:00 amRNSSlimBiome® Medical update
4th Dec 20197:00 amRNSAppointment of European Sales Leader - ProBiotix
6th Nov 201910:38 amRNSHolding(s) in Company
9th Oct 20197:00 amRNSLPLDL® Pharmaceutical GMP process validation
18th Sep 20197:00 amRNSGoFigure® agreement for Southern Africa
28th Aug 201910:00 amRNSDirector's Dealing
28th Aug 20197:00 amRNSHolding(s) in Company
28th Aug 20197:00 amRNSDirectorate Change
28th Aug 20197:00 amRNSHalf-year Report
12th Aug 20197:00 amRNSManufacturing, supply and profit sharing agreement
29th Jul 20194:03 pmRNSTransfer of certain SkinBioTherapeutics plc shares
18th Jul 20197:00 amRNSOnline distribution agreement - SlimBiome® Medical
11th Jul 20197:00 amRNSScientific and commercial update
3rd Jul 20197:00 amRNSLicense agreement for LPLDL® in Japan
1st Jul 20197:00 amRNSLPLDL® license agreement with Kappa Bioscience AS
25th Jun 20197:00 amRNSAppointment of goetzpartners securities Limited
24th Jun 20197:00 amRNSManufacturing agreement with Agropur
11th Jun 20194:55 pmRNSResult of AGM
10th Jun 20197:00 amRNSLicense agreement for CholBiome® in Vietnam
29th May 20193:17 pmRNSDirector's Dealing
28th May 20197:00 amRNSAppointment of CEO of ProBiotix Health
22nd May 20197:00 amRNSGoFigure® distribution agreement for Poland
20th May 20197:00 amRNSLicense agreement for LPLDL®

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.